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Abstract: Urticarial vasculitis (UV) is a subset of cutaneous vasculitis
(CV), characterized clinically by urticarial skin lesions of more than
24 hours’ duration and histologically by leukocytoclastic vasculitis. We
assessed the frequency, clinical features, treatment, and outcome of a series
of patients with UV. We conducted a retrospective study of patients with
UV included in a large series of unselected patients with CV from a uni-
versity hospital. Of 766 patients with CV, UV was diagnosed in 21 (2.7%;
9 male and 12 female patients; median age, 35 yr; range, 1Y78 yr; inter-
quartile range, 5Y54 yr). Eight of the 21 cases were aged younger than
20 years old. Potential precipitating factors were upper respiratory tract
infections and drugs (penicillin) (n = 4; in all cases in patients aged G20 yr),
human immunodeficiency virus (HIV) infection (n = 1), and malignancy
(n = 1). Besides urticarial lesions, other features such as palpable purpura
(n = 7), arthralgia and/or arthritis (n = 13), abdominal pain (n = 2), ne-
phropathy (n = 2), and peripheral neuropathy (n = 1) were observed.
Hypocomplementemia (low C4) with low C1q was disclosed in 2 patients.
Other abnormal laboratory findings were leukocytosis (n = 7), increased
erythrocyte sedimentation rate (n = 6), anemia (n = 4), and antinuclear
antibody positivity (n = 2). Treatment included corticosteroids (n = 12),
antihistaminic drugs (n = 6), chloroquine (n = 4), nonsteroidal anti-
inflammatory drugs (n = 3), colchicine (n = 2), and azathioprine (n = 1).
After a median follow-up of 10 months (interquartile range, 2Y38 mo)
recurrences were observed in 4 patients. Apart from 1 patient who died
because of an underlying malignancy, the outcome was good with full
recovery in the remaining patients. In conclusion, our results indicate that
UV is rare but not exceptional. In children UV is often preceded by an
upper respiratory tract infection. Urticarial lesions and joint manifestations
are themost frequent clinical manifestation. Low complement serum levels
are observed in a minority of cases. The prognosis is generally good, but
depends on the underlying disease.
(Medicine 2014;93: 53Y60)
Abbreviations: ANA = antinuclear antibodies, ANCAs =
antineutrophil cytoplasmic antibodies, CV = cutaneous vasculitis,
ESR = erythrocyte sedimentation rate, HIV = human
immunodeficiency virus, IQR = interquartile range, NSAIDs =
nonsteroidal antiinflammatory drugs, RF = rheumatoid factor,
SLE = systemic lupus erythematosus, UV = urticarial vasculitis.
INTRODUCTION
The vasculitides are a heterogeneous group of conditionscharacterized by blood vessel inflammation and necrosis.16
Urticarial vasculitis (UV) is a subset of cutaneous vasculitis (CV)
described byMcDuffie et al34 in 1973 and characterized clinically
by urticarial skin lesions lasting longer than 24 hours and histo-
logically by vasculitis. Urticarial skin lesions in this condition
consist of an eruption of erythematous wheals that clinically re-
semble urticaria but histologically show changes of leukocytoclastic
vasculitis.38,50 UV may be divided into normocomplementemic
and hypocomplementemic variants. Both subsets can be associ-
ated with systemic symptoms such as angioedema, arthralgia or
arthritis, abdominal or chest pain, fever, pulmonary disease, renal
disease, episcleritis, uveitis, and Raynaud phenomenon. The hypo-
complementemic form is more often associated with systemic
symptoms and has been associated with connective tissue disease
such as systemic lupus erythematosus (SLE).43,49
The incidence of UV remains unclear. Because of that, we
assessed the frequency, clinical features, treatment, and outcome
of all patients diagnosed as having UV from a large series of un-
selected patients with CV.
PATIENTS AND METHODS
Patient Population
We reviewed the case records of patients from a teaching
reference hospital in Northern Spain (Hospital Universitario
Marqués de Valdecilla, Santander) in whom CV was diagnosed
from January 1976 to December 2011. Methods were similar to
those previously reported.4 Briefly, the diagnosis of CVwas based
on either 1) a skin biopsy showing characteristic pathologic find-
ings of vasculitis, 2) the presence of typical nonthrombocytopenic
palpable purpura, or 3) a clinically evident syndrome in the
pediatric age.
UV was considered to be present when the patient had urti-
carial lesions (Figures 1A and 1B) lasting more than 24 hours
and a skin biopsy showed leukocytoclastic vasculitis (Figures 2A
and 2B). An exception to that was considered in 2 patients aged
1 year presenting with typical urticarial lesions lasting more than
24 hours in whom the pediatricians did not perform a skin biopsy.
Clinical and Laboratory Definitions
We used the following definitions: 1) Patients aged older than
20 years were considered adults. The cutoff of 20 years was chosen
because this age was proposed as a criterion by the American
College of Rheumatology.36,37 2) Fever was defined as an axillary
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temperature 937.7-C. 3) Constitutional syndrome: asthenia and/
or anorexia, and weight loss of at least 4 kg. 4) Joint symptoms
included arthralgia and/or joint effusion. 5) Gastrointestinal
manifestations: bowel angina (diffuse abdominal pain worsening
after meals), gastrointestinal bleeding (melena, hematochezia, or
positive stool Guaiac test), nausea and/or vomiting. 6) The ne-
phropathy was categorized as mild or severe. Mild nephropathy
included those patients with microhematuria (Q5 red cells/high
power field) without reaching nephritic syndrome and/or pro-
teinuria that did not reach the nephrotic range. 7) A relapse was
considered to be present when a patient previously diagnosed as
having CVand asymptomatic for at least 1 month presented again
a new flare of cutaneous lesions. Anemia was defined as a he-
moglobin level e110 g/L. Leukocytosis was defined if awhite cell
count was Q11  109/L, and leukopenia was defined as a leuko-
cyte count G3 109/L. TheWestergren erythrocyte sedimentation
rate (ESR) in mm/h was considered elevated when it was higher
than 15 or 20 mm/h for male or female patients, respectively.
Clinical Study
ln most patients presenting with CV, routine laboratory
studies, including complete blood cell count, coagulation studies,
and liver and renal function tests, were performed at the time of
diagnosis. In addition, ESR, routine urinalysis, and chest radio-
graphs were performed.
An immunologic profile was carried out in most adults (but
only in a minority of children). It included rheumatoid factor (RF),
performed until the late 1980s by quantitative latex agglutination
test, and later by nephelometry; antinuclear antibodies (ANA), by
indirect immunofluorescence using rodent tissues as substrate
until the late 1980s and since then by Hep-2 cells; serum levels
of C3 and C4, first by radial immunodiffusion and more recently
by nephelometry; and cryoglobulins. The composition of the cryo-
precipitate was determined by double immunodiffusion with spe-
cific antibodies. Antineutrophil cytoplasmic antibodies (ANCAs)
were assessed initially by indirect immunofluorescence on alcohol-
fixed neutrophils, and later, by enzyme-linked immunosorbent
assay (ELISA) with purified proteinase-3 and myeloperoxidase.
ANCAs were only assessed in patients seen since 1990. Other
tests, such as anti-nDNA antibodies (by immunofluorescence
with Crithidia luciliae as substrate), blood cultures, Guaiac test
for occult blood, bone marrow biopsy, and serology for hepatitis
B, C, or human immunodeficiency virus (HIV) infection, were
performed only when they were clinically indicated.
Data Collection and Statistical Analysis
Data were first reviewed and then analyzed to study etio-
logic, clinical, laboratory, and histopathologic features, as well as
treatment and prognosis. Data were extracted from patients’ clin-
ical records according to a specifically designed protocol, reviewed
FIGURE 1. Typical urticarial lesions in a patient presenting with urticarial vasculitis (A and B; residual purpuric lesions can
be observed in B).
FIGURE 2. A, Perivascular and interstitial infiltrate of polymorphonuclear neutrophils and eosinophils ( white arrow) with leukocytoclastic
venulitis. (Hematoxylin-eosin stain; original magnification  100.) B, Perivascular eosinophilic infiltrate with fibrin deposits (short
white arrow) and karyorrhexis (long white arrow). (Hematoxylin-eosin stain; original magnification  200.)
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for confirmation of the diagnosis, and stored in a computerized file.
To minimize entry error all the data were double checked. A com-
parative study between UVand the remaining CVwas performed.
The statistical analysis was performed with the STATISTICA
software package (Statsoft Inc. Tulsa, OK). Results were expressed
as mean T standard deviation for variables with a normal
TABLE 1. Main Features of 21 Patients With Urticarial Vasculitis From a Single Center
Case Age/Sex Main Clinical Features Laboratory Data Treatment for the Vasculitis Outcome
1 67/W Wheals over 24 hours,
arthritis, hypoesthesia
Normal C3, C4 and C1q Antihistaminic drugs and
colchicine for 2 months
Resolution without relapses
2 62/M Wheals over 24 hours,
arthritis
Normal C3 and C4,
negative RF and ANA
Corticosteroids (prednisone:









of C4 and C1q, positive RF,
negative ANA
Corticosteroids (prednisone:








normal C3 and C4, negative
RF and ANA
Corticosteroids (prednisone:
initial dose- 30 mg/day) and
chloroquine for 3 months
Resolution without relapses
5 44/W Wheals over 24 hours,
arthralgia
Elevated ESR, leukocytosis,
normal C3 and C4
Corticosteroids (prednisone:
initial dose- 30 mg/day) and
chloroquine for 12 months
Subsequently UV relapsed
in 2 occasions
6 78/M Wheals over 24 hours,
palpable purpura,
arthralgia
Normal C3 and C4, negative
RF and ANA
Corticosteroids (prednisone:
initial dose- 15 mg/day)
for 3 months
Resolution without relapses
7 67/M Wheals over 24 hours,
abdominal pain
Leukocytosis, normal C3 and
C4, negative RF and ANA
Corticosteroids (prednisone:








Normal C3 and C4, negative
RF and ANA
Corticosteroids (prednisone:




9 32/W Wheals over 24 hours,
arthralgia
Normal C3 and C4, negative
RF and ANA
Corticosteroids (prednisone:
initial dose- 30 mg/day)
for 3 months
Resolution without relapses
10 42/M Wheals over 24 hours,
arthralgia, fever




30 mg/day) and cytotoxic
agents for 5 years
UV relapsed in 2 occasions
11 28/W Wheals over 24 hours Leukocytosis, normal C3
and C4, negative RF,
positive ANA (1/160)
Corticosteroids (prednisone:
initial dose-5 mg/day) and
chloroquine for 5 months
Resolution without relapses




normal C3 and C4,
negative RF and ANA
NSAIDs for 2 weeks Resolution without relapses
13 40/W Wheals over 24 hours,
arthritis, fever
Anemia, normal C3 and C4,
negative RF, positive
ANA (1/160)
NSAIDs for 6 months Subsequently UV relapsed
3 times. Finally, the
patient died due to
underlying malignancy
14 14/W Wheals over 24 hours Anemia, elevated ESR,
decrease of C4 and C1q,
negative RF and ANA
Corticosteroids (prednisone:
initial dose- 30 mg/day)
for 2 months
Resolution without relapses
15 3/M Wheals over 24 hours,
cough
Leukocytosis Antihistaminic drugs for
2 weeks
Resolution without relapses




initial dose- 5 mg/day)
for 1 week
Resolution without relapses
17 2/M Wheals over 24 hours,
arthritis, cough
Leukocytosis None Resolution without relapses









None Resolution without relapses







21 2/M Wheals over 24 hours Normal peripheral
blood smear
None Resolution without relapses
Abbreviations: M = man, W = woman, RF = rheumatoid factor, ANA = Antinuclear antibodies, ESR = Erythrocyte Sedimentation Rate mm/1st
hour, NSAIDs = Nonsteroidal antiinflammatory drugs, UV = Urticarial vasculitis.
Leukocytosis: if a white cell count was Q11  109/ liter. Anemia: if hemoglobin was G110 g/liter.
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distribution, or as median, range, or interquartile range (25th,
75th) (IQR) for those not normally distributed. Continuous vari-
ables (normally and not normally distributed) were comparedwith
the 2-tailed Student t-test or the Mann-Whitney U test, respec-
tively. The chi-square test or the Fisher exact test was used for
dichotomous variables. Statistical significance was considered as a
p value G 0.05.
The current study was a retrospective review of cases diag-
nosed with UV. No specific request for the review was made to
our local ethical committee for that purpose. However, ethical
committee approval (Ethical Committee of Cantabria, Spain) was
obtained to perform studies on genetic markers of patients with
CV that are underway.
RESULTS
We assessed the medical records of a series of 766 patients
(346 female/420 male patients) from a university hospital in
Santander, Spain, in whom CV was diagnosed between January
1976 and December 2011. The mean age of the entire series was
34.0 T 27.5 years (range, 1Y95 yr). Of the 766 patients, 421 (178
female/243 male patients) were aged more than 20 years, with a
mean age of 55.6 T 17.5 years (range, 24Y95 yr).
Frequency and Demographic Data of Patients
With UV
UV was diagnosed in 21 of 766 patients with CV: 9 male
and 12 female patients; median age, 35 yr (range, 1Y78 yr; IQR,
5Y54 yr). These patients constituted 2.7% of the whole series of
766 of CV patients. Thirteen of them were aged more than
20 years (5 men and 8 women; median age, 44 yr; range,
28Y78 yr; IQR, 37Y67 yr). They constituted 3.1% of the series of
421 adults with CV.
Main Clinical Features
Skin lesions were the first clinical manifestation in the
21 patients with UV. The most frequent skin lesions were wheals
TABLE 2. Differences Between Patients With Urticarial Vasculitis (UV) and the Remaining Patients With Cutaneous Vasculitis (CV)
UV (n = 21) CV Without UV (n = 745) p
Demographic data
Age median [IQR range] (years) 35 [5Y54] 30 [7Y59] 0.91
Sex n (%)
Men/Women 9 (42.86%)/12 (57.14%) 411 (55.17%)/334 (44.83%) 0.26
Precipitating events
Infection 5 (23.81%) 270 (36.24%) 0.24
Drug intake 4 (19.05%) 229 (30.74%) 0.25
Underlying neoplasia 1 (4.76%) 15 (2.01%) 0.39
Skin lesions
Wheals over 24 hours 21 (100%) 0 (0%) G0.01
Other skin lesions 7 (33.33%) 745 (100%) G0.01
Duration (days) mean T SD 10.71 T 9.35 13.26 T 11.32 0.31
Constitutional syndrome 1 (4.76%) 44 (5.91%) 0.82
Fever 2 (9.52%) 162 (21.74%) 0.18
Joint manifestations 13 (61.90%) 375 (50.34%) 0.29
Gastrointestinal involvement 2 (9.52%) 291 (39.06%) G0.01
Nephropathy 2 (9.52%) 243 (32.62%) 0.03
Neuropathy 1 (4.76%) 23 (3.09%) 0.66
Routine laboratory findings
Hemoglobin (g/L), median (IQR) 10.9 (10Y12.3) 12.3 (10.3Y13.7) 0.15
Leukocyte ( 109/L), median (IQR) 12,400 (11,700Y14,600) 13,400 (12,200Y15,600) 0.31
ESR mm 1st hour, median (IQR) 30 (21Y35) 40 (27Y63) 0.25
Abnormal urinalysis no. (%) 2 (9.52%) 281 (37.72%) G0.01
Any cytopenia no. (%) 5 (23.81%) 136 (18.25%) 0.52
Anemia 4 (19.05%) 102 (13.69%) 0.48
Leukopenia 0 (0%) 20 (2.68%) 0.45
Thrombocytopenia 0 (0%) 14 (1.88%) 0.53
Immature cells in peripheral blood smear no. (%) 1 (4.76%) 7 (0.94%) 0.09
Positive ANAs* 2/11 tested (18.18%) 85/320 tested (26.56%) 0.53
Positive RF* 1/11 tested (9.09%) 72/332 tested (21.69%) 0.31
Low C3 and/or C4* 2/14 tested (14.29%) 96/324 tested (29.63%) 0.22
Abbreviations: IQR = Interquartile range, Joint manifestations = arthralgia and/or arthritis, ESR = Erythrocyte Sedimentation Rate in mm/1st hour,
RF = rheumatoid factor, ANA = antinuclear antibodies, C3 and C4 fractions of complement.
Routine laboratory tests were done in all patients at the time of diagnosis.
Leukopenia was defined as a leukocyte count G3  109/liter, anemia as hemoglobin G110 g/liter.
P significant e 0.05.
* Values no. positive/total no. tested (%).
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lasting more than 24 hours that were painful and burning (Table 1).
In most cases cutaneous lesions were located in the extremities
and trunk and had a mean duration of 10.71 T 9.35 days. Other
clinical manifestations were arthralgia and/or arthritis (in 13 cases).
Two patients had abdominal pain and another 2 patients had ne-
phropathy (in both cases microhematuria). Fever was present in
2 patients, and mononeuritis multiplex in 1 patient. One patient
had paraneoplastic CV (megakaryocytic leukemia).31
Four of the 8 children (defined as patients aged e20 yr) had
an upper respiratory tract infection within the week before the
onset of UV. All of them had been treated with penicillin before
admission. In the group of adults (aged 920 yr), potential asso-
ciation with infection was disclosed in only 1 patient, who was
diagnosed with HIV infection during admission for UV.
None of pediatric patients fulfilled previously established
definitions for Henoch-Schönlein purpura at the time of diagnosis
or during follow-up. Overall, in patients aged e20 years, the clin-
ical features were usually milder than in adults.
Laboratory and Pathologic Findings
The registered immunologic parameters of our patients were
C3, C4, C1q, RF, ANA, and ANCAs. Children less commonly
had laboratory abnormalities. As shown in Table 1, hypocomple-
mentemia (low C4) was observed in 2 of 21 patients with UV. In
both cases it was associated with low C1q. Other abnormal lab-
oratory data observed were leukocytosis (7 cases), increased ESR
(6 cases), anemia (4 cases), positive ANA (2 cases), and positive
RF (1 case). None of the patients with positive ANA or RF de-
veloped SLE, rheumatoid arthritis, or any other connective tissue
disease during follow-up.
Skin punch biopsy was performed in 19 patients. As previ-
ously mentioned, it was not performed in 2 patients aged 1 year. In
these 2 pediatric cases the clinical features were compatible with
UV. Characteristic histologic findings, such as neutrophilic infil-
tration; leukocytoclasia; and fibrinoid necrosis into the vesselwall
of arterioles, capillaries, and postcapillary venules, were observed
in the 19 patients in whom a skin biopsy was performed.
Treatment and Outcome
The most common drugs used in the management of UV
were corticosteroids (12 cases), antihistaminic drugs (6 cases), chlo-
roquine (4 cases), nonsteroidal antiinflammatory drugs (NSAIDs)
(3 cases), and colchicine (2 cases) (see Table 1). An immuno-
suppressive drug (azathioprine) was required in 1 patient. After a
median follow-up of 10 months (IQR, 2Y38 mo) recurrences were
observed in 4 (19%) of 21 patients. One patient died because of
an underlying malignancy, while the remaining patients had full
recovery without complications. Relapses were less frequent in
the younger age group.
Differences Between Patients With UV and the
Remaining Patients With CV
We performed a comparative analysis of differences between
patients with UV and the remaining patients with CV (Table 2).
A history of previous infection or drug intake before the onset of
the vasculitis was less common in the group of patients with UV
than in the remaining patients with CV, but the difference was not
statistically significant. In addition, gastrointestinal involvement
and nephropathy were less frequent in patients with UV.
DISCUSSION
The term UV encompasses a syndrome characterized histo-
logically by a small vessel vasculitis in which urticarial skin lesions
have a duration of more than 24 hours, unlike what it is observed
in cases of urticaria.8,12,28,41,48 UV may be associated with hypo-
complementemia and the presence of IgG anti-C1q. Since UV has
specific clinical and serologic characteristics, it has been proposed
as a separate entity different from the rest of CV. However, the
actual proportion of cases with UV in the series of patients with
CV remains unknown. In the current series the frequency of UV
was 2.7% of the whole series of CV including pediatric patients,
and 3.1% when we specifically assessed the frequency in adults
with CV. Therefore, our results indicate that UV is rare but not
exceptional.
The etiology of UV remains unclear. The pathogenesis of
UV is thought to be immune mediated.23 This is a type III hy-
persensitivity reaction in which antigen-antibody complexes are
deposited in the vascular lumen. Many different antigens, both
endogenous and exogenous, have been implicated in the forma-
tion of antibodies leading to the generation of immune complexes
that are deposited in the blood vessels of patients with UV.
Complement is activated by the classical pathway, generating
C3a and C5a. These anaphylatoxins stimulate the release of mast
cells, promoting neutrophil chemotaxis and increased permeability
of vessels.18,24,53 When neutrophils arrive at the site of inflam-
mation, they acquire a phagocytic function and release proteolytic
enzymes which further aggravate tissue destruction and edema.3
The C1q molecule has a collagen-like region that forms an
antibody-binding site. IgG binds to the Fc fragment of C1q mol-
ecules, thereby activating the classical pathway of complement.
The activation of this pathway induces mast cell degranulation
and the synthesis of cytokines and chemokines, leading to increased
vascular permeability, chemotaxis of neutrophils, and increased
immune complex deposits.18,24,53 C1q autoantibodies may also
play a role in the pathogenesis of the pulmonary disease seen in
some cases of UV.10,24,33 A cross-reactivity between antibodies to
C1q and pulmonary surfactant apoproteins that contain collagen-
like regions similar to C1q has been proposed.2,5 Some lympho-
proliferative disorders have been associated with anti-C1q antibodies.
Paraproteins may activate C1q circulating through the classic
complement pathway thus leading to the depletion of C1q esterase
inhibitors.10,24,33
Electronic microscopy indicates that activated platelet
aggregates may also play an important role in the pathogenesis
of UV.10,39 Destruction of vessels along with the presence of an
endothelial inflammatory infiltrate composed of neutrophils and
mononuclear cells was observed 32 hours after the intradermal
injection of platelet-activating factor.10
UV may occur at any age, but it is more common in the fifth
decade. Women are affected twice as often as men.11 It may
present with a wide clinical spectrum, ranging from skin lesions
exclusively to a severe systemic disease. Clinically, the lesions of
UV last longer (generally 3Y7 d) than those of ordinary urticaria.
The hives present with burning and pain and may leave residual
bruising or hyperpigmentation of the skin.54 Some patients may
have an associated angioedema in the face or hands. The most
common noncutaneous manifestation is arthralgia, but kidney
and pulmonary disease and gastrointestinal symptoms have also
been reported.3,19 In the current series of UV, arthralgia and
arthritis were the most common noncutaneous manifestations.
In most cases, UV is an isolated condition. However, it may
present as an entity associated with different conditions, including
connective tissue diseases such as SLE or Sjögren syndrome;
systemic necrotizing vasculitis; or infections, such as hepatitis B
or C, infectious mononucleosis, Coxsackie, and Lyme disease.
UV has been described in association with solid or hematologic
malignancies.7,15,20,29,31,46,47,51 We reported31 a 40-year-old woman
in whom megakaryocytic leukemia was diagnosed. UV has also
been described in a few patients after exercise.25 In this regard,
Di Stefano et al13 reported a 42-year-old man who presented with
a 1-month history of recurring erythematous wheals over the
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lower extremities that occurred a few hours after physical exer-
cise. Each lesion persisted for more than 24 hours but disappeared
in less than 3 days, leaving the area involved with slight pigmen-
tation. Skin biopsy of an urticarial lesion disclosed leukocytoclastic
vasculitis, which is the main histologic criterion for differentiating
UV from urticaria. Incidentally, a teratoma was diagnosed in the
patient. It is noteworthy that once the tumor was surgically re-
moved, the patient had no more UV flares.13
Most reports on UV are limited to the description of a single
case, emphasizing that UV may be an uncommon type of vascu-
litis. Nevertheless, Kulthanan et al27 reported a series of 64 cases
in individuals aged more than 18 years. More than 90% of them
had erythematous wheals lasting more than 24 hours. Most cases
were idiopathic (45 E70%^ of 64 patients). Nonetheless, 19 (30%)
patients had UVassociated with different conditions: 8 cases had
UV in the context of an infection (upper respiratory tract infection
in 6 patients, and HIV and syphilis in 1 patient each); 5 patients
had UV in association with drugs (NSAIDs in 3 patients, and
antibiotic and interferon in 1 patient each); 5 patients had UVas a
paraneoplastic vasculitis (breast, ovary, thyroid, colon, and pitui-
tary tumors, respectively); and 1 patient had UV in the setting of
SLE. In our current series, 100% of patients had urticarial lesions
of over 24 hours’ duration. Seven patients had palpable purpura,
and 1 of them developed ulcers in the lower limbs.
Several uncommon associations of UV with different con-
ditions have been reported. Ferreira et al14 reported a 38-year-old
woman presenting with erythematous, violaceous plaques with a
serpinginous and unusual appearance located on the left shoulder,
left thigh, and right buttock, evolving in 5 days, which eventually
became generalized, and the patient developed thyroiditis. In
2010, Hughes et al21 reported the case of a patient with UV fol-
lowing H1N1 vaccination. In some cases UV has been reported to
occur in the setting of an IgM monoclonal gammopathy consti-
tuting what is called Schnitzler syndrome. This syndrome, first
described in 1972,30,44 is characterized by UV, IgM gammopathy,
fever, bone pain, and arthralgia and/or arthritis. In addition, UV
has been described in patients with inflammatory bowel disease or
Guillain-Barré syndrome, and following exposure to sun and
cold. One noteworthy case was reported by Macêdo et al32 of a
12-year-old boy with SLE and dermatomyositis associated with
UV syndrome. To our knowledge, this was the first case of triple
association (2 connective tissue diseases plus UV) described in
the literature.
According to the complement results, UV can be divided into
normocomplemetemic or hypocomplementemic.9 Patients with
hypocomplementemic UV syndrome are more likely to have an
associated connective tissue disease and systemic symptoms than
are patients with UV and normal complement levels,43 and they
may also have IgG antibodies to the collagen-like domain of C1q.52
Hypocomplementemic UV, like SLE, has been associated with the
presence of anti-cell-endothelial antibodies. In our current series
only 2 (9.5%) of the 21 patients had low levels of complement.
This result is in accordance with the results of Kulthanan et al,27
who described 9.7% of patients with hypocomplementemic UV.
However, the results contrast with other studies that described
higher frequencies of hypocomplementemia ranging from 20.6%
to 64%.6,28,35,45
In the laboratory tests RF may be positive and in hypocom-
plementemic UV there is a decrease of CH50, C3, and/or C4.
When ANA are positive a diagnosis of SLE should be ruled out.
A differential diagnosis with several conditions resembling
UV is required when this vasculitis is suspected. Unlike UV,
ordinary urticaria (hives) presents with spontaneous wheals any-
where on the body lasting less than 24 hours. The lesions are itchy
but not painful or burning, and the biopsy shows a mixed
perivascular infiltrate without vasculitis. A condition that may
mimic UV is neutrophilic urticaria, which is a variant of urticaria
responsive to antihistaminic drugs characterized by chronic urti-
caria and neutrophil infiltration without vasculitis. Another con-
dition to be excluded is urticarial arthritis, which is characterized
by bouts of arthritis, urticaria (lasting G24 h), and facial angio-
edema inHLA-B51-positive patients.40 Some patientswith urticarial
arthritis may have a biopsy showing leukocytoclastic vasculitis,
while others may have only an infiltrate without damage in the
vessel wall. Finally, as discussed above, in cases of UVwe have to
rule out the presence of an underlying connective tissue disease,
mainly SLE, and a malignancy. Other conditions that should be
considered in the differential diagnosis of a patient presenting
with UVare shown in Table 3.
Treatment of UV differs from treatment of ordinary chronic
urticaria, and depends on whether there is systemic involvement
and/or an underlying disease. Corticosteroids are generally the
most effective drugs, but some patients with UVmay require high
doses, with relapses relatively common when the corticosteroid
dose is tapered. Antihistaminic drugs and NSAIDs can be used in
cases of UV limited to the skin. In cases refractory to these medi-
cations other drugs such as colchicine, dapsone, azathioprine, or
hydroxychloroquine may be used. Cases reporting improvement
of joint symptoms following intramuscular gold therapy have
been described.46 There are also case reports of patients with refrac-
tory UV responding to rituximab43 and mycophenolate mofetil.55
In the series by Kulthanan et al,27 the drugs used included oral
antihistamines (68.8%), colchicine (65.6%), NSAIDs (42.4%),
and systemic corticosteroids (40.6%). In our current series the
most common drugs prescribed were corticosteroids and antihis-
taminic drugs, and only a single patient required immunosup-
pressive therapy.
Plasmapheresis has proved beneficial in the treatment of
some patients with CV and UV1,17,22,42 because it allows the re-
moval of the circulating immune complexes. Kartal et al26 reported
the case of a 35-year-old woman with a 9-year history of recurrent
episodes of UV refractory to different therapies who achieved
clinical improvement following plasmapheresis.
In cases associated with a specific disease, the prognosis
depends on the underlying disease. In idiopathic cases UV is
usually benign, but it can follow a chronic course lasting up to
3 years.
In conclusion, our results indicate that UV is rare but not
exceptional. In children, UV is often preceded by an upper respi-
ratory tract infection. Urticarial lesions and joint manifestations are
the most frequent clinical manifestations. Low complement serum
levels are observed in a minority of cases. The prognosis is gen-
erally good but depends on the underlying disease.
TABLE 3. Main Entities That Should be Considered in the
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